Additional Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Charleston SC. 29425
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Birmingham AL. 35233
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Iowa City IA. 52242
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Denver CO. 80206
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Albany NY. 12208
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Jacksonville FL. 32209
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Philadelphia PA. 19140
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    New York NY. 10029
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Chicago IL. 60611
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Greenville NC. 27858
    View Details

  • A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

    University of Southern California
    Los Angeles CA. 90033
    View Details

  • A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

    Cedars Sinai Medical Center
    Los Angeles CA. 90048
    View Details

  • A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

    University of Alabama
    Birmingham AL. 35294
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    UCLA Health Westwood Medical Plaza
    Westwood CA. 90095
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Chicago IL. 60153
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Salt Lake City UT. 84112
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    San Diego CA. 92093
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Houston TX. 77204
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Chicago IL. 60611
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    New York NY. 10027
    View Details